News Immuneering Corporation

Equities

IMRX

US45254E1073

Real-time Estimate Cboe BZX Other stock markets 09:57:36 2024-04-26 am EDT			5-day change	1st Jan Change
1.48 ^USD	+3.50%		-18.89%	-80.14%

Apr. 09	Immuneering Corporation Presents Preclinical Data At the American Association for Cancer Research Annual Meeting	CI
Apr. 02	Mizuho Adjusts Price Target on Immuneering to $8 From $20 on Revised Revenue Assumptions for Lead Asset IMM-1-104, Keeps Buy Rating	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

IMM-1-104 is Synergistic with Chemotherapy in Pancreatic Cancer Models	Apr. 09	GL
Immuneering Corporation Presents Preclinical Data At the American Association for Cancer Research Annual Meeting	Apr. 09	CI
Immuneering to Participate in the 23rd Annual Needham Virtual Healthcare Conference	Apr. 03	GL
Mizuho Adjusts Price Target on Immuneering to $8 From $20 on Revised Revenue Assumptions for Lead Asset IMM-1-104, Keeps Buy Rating	Apr. 02	MT
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations	Mar. 27	GL
Immuneering Announces First Patient Dosed in its Phase 1/2a Trial of IMM-6-415 to Treat Advanced Solid Tumors with RAF or RAS Mutations	Mar. 27	AQ
Immuneering Announces First Patient Dosed in Its Phase 1/2A Trial of Imm-6-415 to Treat Advanced Solid Tumors with Raf or Ras Mutations	Mar. 27	CI
March Madness Market Movers: INBS, NCMI, CIFR, IMRX, STI	Mar. 20	AQ
North American Morning Briefing : Investors -2-	Mar. 18	DJ
Sector Update: Health Care Stocks Ease Late Afternoon	Mar. 15	MT
Sector Update: Health Care	Mar. 15	MT
Immuneering Shares Decline After Analysts Downgrades, Phase 1 Cancer Therapy Data	Mar. 15	MT
Jefferies Downgrades Immuneering to Hold From Buy, Cuts Price Target to $3 From $16	Mar. 15	MT
Needham Adjusts Price Target on Immuneering to $15 From $20, Maintains Buy Rating	Mar. 15	MT
Chardan Lowers Price Target on Immuneering to $16 From $21, Keeps Buy Rating	Mar. 15	MT
North American Morning Briefing : Inflation -2-	Mar. 15	DJ
Guggenheim Downgrades Immuneering to Neutral From Buy	Mar. 15	MT
TD Cowen Downgrades Immuneering to Market Perform From Outperform	Mar. 15	MT
Transcript : Immuneering Corporation - Special Call	Mar. 14
Immuneering Announces Positive Topline Results from Phase 1 Portion of its Phase 1/2a Clinical Trial of IMM-1-104 in RAS-Mutant Solid Tumors	Mar. 14	GL

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Immuneering Corporation

Equities

IMRX

US45254E1073

Summary

Filters